A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 11, 2015

Primary Completion Date

October 13, 2015

Study Completion Date

October 13, 2015

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Albiglutide 50 mg

Albiglutide 50 mg pen is a single-use fixed dose, fully disposable pen injector system for SC delivery in the abdomen containing 67 mg lyophilized albiglutide and 0.65 mL diluents designed to deliver a dose of 50 mg in a volume of 0.5 mL after reconstitution

DRUG

Placebo

Placebo is a single-use fixed dose, fully disposable pen injector system for SC delivery of 0.5 mL injector volume in the abdomen

DRUG

CCK (Kinevac)

CCK (Kinevac) will be infused intravenously. Kinevac is supplied in vials containing 5 microgram (mcg)/vial. Infusion prepared aseptically by adding 5 mL of Sterile Water for Injection United States Pharmacopeia (USP) to the vial to create a solution of 1 mcg/mL. Infuse 0.003 mcg/kg dose in 100 mL of Sodium Chloride Injection USP, 0.9%

Trial Locations (1)

21225

GSK Investigational Site, Baltimore

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02496221 - A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects | Biotech Hunter | Biotech Hunter